Literature DB >> 24603819

Transglutaminase 2: a new player in bronchopulmonary dysplasia?

Thilo J Witsch1, Gero Niess2, Elpidoforos Sakkas2, Tatyana Likhoshvay2, Simone Becker2, Susanne Herold1, Konstantin Mayer1, István Vadász1, Jesse D Roberts3, Werner Seeger2, Rory E Morty4.   

Abstract

Aberrant remodelling of the extracellular matrix in the developing lung may underlie arrested alveolarisation associated with bronchopulmonary dysplasia (BPD). Transglutaminases are regulators of extracellular matrix remodelling. Therefore, the expression and activity of transglutaminases were assessed in lungs from human neonates with BPD and in a rodent model of BPD. Transglutaminase expression and localisation were assessed by RT-PCR, immunoblotting, activity assay and immunohistochemical analyses of human and mouse lung tissues. Transglutaminase regulation by transforming growth factor (TGF)-β was investigated in lung cells by luciferase-based reporter assay and RT-PCR. TGF-β signalling was neutralised in vivo in an animal model of BPD, to determine whether TGF-β mediated the hyperoxia-induced changes in transglutaminase expression. Transglutaminase 2 expression was upregulated in the lungs of preterm infants with BPD and in the lungs of hyperoxia-exposed mouse pups, where lung development was arrested. Transglutaminase 2 localised to the developing alveolar septa. TGF-β was identified as a regulator of transglutaminase 2 expression in human and mouse lung epithelial cells. In vivo neutralisation of TGF-β signalling partially restored normal lung structure and normalised lung transglutaminase 2 mRNA expression. Our data point to a role for perturbed transglutaminase 2 activity in the arrested alveolarisation associated with BPD. © ERS 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24603819      PMCID: PMC4212268          DOI: 10.1183/09031936.00075713

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

1.  Bronchopulmonary dysplasia.

Authors:  A H Jobe; E Bancalari
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

Review 2.  Transglutaminases: crosslinking enzymes with pleiotropic functions.

Authors:  Laszlo Lorand; Robert M Graham
Journal:  Nat Rev Mol Cell Biol       Date:  2003-02       Impact factor: 94.444

Review 3.  Recent advances in late lung development and the pathogenesis of bronchopulmonary dysplasia.

Authors:  Alicia Madurga; Ivana Mizíková; Jordi Ruiz-Camp; Rory E Morty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-08       Impact factor: 5.464

4.  Collagen scaffolding during development and its deformation with chronic lung disease.

Authors:  Donald W Thibeault; Sherry M Mabry; Ikechukwu I Ekekezie; Xiaoming Zhang; William E Truog
Journal:  Pediatrics       Date:  2003-04       Impact factor: 7.124

5.  Transglutaminase type 1 and its cross-linking activity are concentrated at adherens junctions in simple epithelial cells.

Authors:  T Hiiragi; H Sasaki; A Nagafuchi; H Sabe; S C Shen; M Matsuki; K Yamanishi; S Tsukita
Journal:  J Biol Chem       Date:  1999-11-26       Impact factor: 5.157

6.  Regulation of type I and type II transglutaminase in normal human bronchial epithelial and lung carcinoma cells.

Authors:  T M Vollberg; M D George; C Nervi; A M Jetten
Journal:  Am J Respir Cell Mol Biol       Date:  1992-07       Impact factor: 6.914

Review 7.  Transglutaminases: nature's biological glues.

Authors:  Martin Griffin; Rita Casadio; Carlo M Bergamini
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

8.  In vivo transglutaminase type 1 expression in normal lung, preinvasive bronchial lesions, and lung cancer.

Authors:  Nadine Martinet; Lionel Bonnard; Véronique Regnault; Evelyne Picard; Louise Burke; Joëlle Siat; Gilles Grosdidier; Yves Martinet; Jean-Michel Vignaud
Journal:  Am J Respir Cell Mol Biol       Date:  2003-04       Impact factor: 6.914

9.  Expression of tissue transglutaminase in Balb-C 3T3 fibroblasts: effects on cellular morphology and adhesion.

Authors:  V Gentile; V Thomazy; M Piacentini; L Fesus; P J Davies
Journal:  J Cell Biol       Date:  1992-10       Impact factor: 10.539

10.  Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells.

Authors:  S Kojima; K Nara; D B Rifkin
Journal:  J Cell Biol       Date:  1993-04       Impact factor: 10.539

View more
  7 in total

Review 1.  Animal models of bronchopulmonary dysplasia. The preterm baboon models.

Authors:  Bradley A Yoder; Jacqueline J Coalson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-03       Impact factor: 5.464

Review 2.  Established severe BPD: is there a way out? Change of ventilatory paradigms.

Authors:  Richard Sindelar; Edward G Shepherd; Johan Ågren; Howard B Panitch; Steven H Abman; Leif D Nelin
Journal:  Pediatr Res       Date:  2021-05-19       Impact factor: 3.756

Review 3.  Pathogenesis of bronchopulmonary dysplasia: when inflammation meets organ development.

Authors:  Tayyab Shahzad; Sarah Radajewski; Cho-Ming Chao; Saverio Bellusci; Harald Ehrhardt
Journal:  Mol Cell Pediatr       Date:  2016-06-29

Review 4.  The Extracellular Matrix in Bronchopulmonary Dysplasia: Target and Source.

Authors:  Ivana Mižíková; Rory E Morty
Journal:  Front Med (Lausanne)       Date:  2015-12-23

Review 5.  Looking ahead: where to next for animal models of bronchopulmonary dysplasia?

Authors:  Claudio Nardiello; Ivana Mižíková; Rory E Morty
Journal:  Cell Tissue Res       Date:  2016-12-05       Impact factor: 5.249

Review 6.  The BPD trio? Interaction of dysregulated PDGF, VEGF, and TGF signaling in neonatal chronic lung disease.

Authors:  Prajakta Oak; Anne Hilgendorff
Journal:  Mol Cell Pediatr       Date:  2017-11-07

Review 7.  The Potentials and Caveats of Mesenchymal Stromal Cell-Based Therapies in the Preterm Infant.

Authors:  Judith Gronbach; Tayyab Shahzad; Sarah Radajewski; Cho-Ming Chao; Saverio Bellusci; Rory E Morty; Tobias Reicherzer; Harald Ehrhardt
Journal:  Stem Cells Int       Date:  2018-04-08       Impact factor: 5.443

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.